Interleukin-27 Olink

"IL-27 (interleukin-27) is an IL-6 related cytokine that belongs to the IL-12 family. IL-27 is composed of two subunits, IL-27p28 and Epstein-Barr virus induced gene 3 (EBI3). The main producers of IL-27 are antigen presenting cells, including monocytes, macrophages, and dendritic cells. The expression of the IL-27 full receptor (IL27Ra/gp130) is localized primarily on lymphocytes, monocytes, and osteoclasts. Due to its production and receptor distribution, IL-27 has wide pleiotropic effects on immune responses and can bridge the expanse of innate and adaptive immunity. Additionally, it also possesses both inflammatory and anti-inflammatory functions. Similarly to IL-12, IL-27 can modulate CD4 T cell differentiation into T cell helper type 1 (TH1) and increase IFN? production from both innate and adaptive lymphocytes. Its anti-inflammatory activity is demonstrated by inhibition of TH17, promotion of T regulatory cell growth and survival, and enhancement of IL-10 production. The roles of IL-27 in disease are in direct correlation to its affect on both innate and adaptive leukocytes. As such, IL-27 has both pro and anti-cancer actions, specifically in the tumor microenvironment. It can dampen cancer cell proliferation, migration and invasion, and it can increase cancer cell death, mainly through activation of innate and adaptive cytotoxic cell lymphocytes. However, it also induces PD-L1 expression that can directly suppress cytotoxic lymphocyte activities. In addition, IL-27 also may play a key role in autoimmune diseases, such as rheumatoid arthritis. Elevated circulating levels of IL-27 has been correlated with RA disease activity. However, treatment with IL-27 locally can also reduce joint damage and bone and cartilage erosion, most likely through inhibition of IL-17 and TH17. Other pathways, ranging from atherosclerosis to sepsis can also be modulate by IL-27, again through its ability to affect a variety of leukocytes. "

Swiss-Prot Accession Number: Q14213, Q8NEV9